Tessari Eben 4

What Happened
Tessari Eben, Chief Strategy Officer of Kiniksa Pharmaceuticals International (KNSA), had 2,726 restricted share units (RSUs) convert into Class A ordinary shares on April 7, 2026. To satisfy tax withholding, 846 of those shares were withheld at $48.94 per share, resulting in withholding value of $41,403. The net shares issued to Tessari after withholding were 1,880 shares (2,726 granted minus 846 withheld).

Key Details

• Transaction date: April 7, 2026; Form 4 filed April 8, 2026 (timely filing).
• Conversion/exercise code: M (exercise/conversion of derivative — here RSUs converting to shares).
• Tax/payment code: F (payment of exercise price or tax liability) — 846 shares withheld at $48.94 each, $41,403 total.
• Shares issued on conversion: 2,726; shares withheld for taxes: 846; net issued to insider: 1,880.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes from the filing: F1 — each RSU converts to one Class A ordinary share; F2 — the RSUs vest over four years with 25% vesting each April 7 starting April 7, 2022.

Context

• This was a standard RSU vesting and tax-withholding event (common for equity compensation), not an open-market sale. The "disposed" shares on the Form 4 reflect tax withholding, not a market transaction.
• Such receipts are routine for employee equity plans and do not by themselves indicate a change in the insider’s view of the company.